[go: up one dir, main page]

MX2019011343A - Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes. - Google Patents

Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.

Info

Publication number
MX2019011343A
MX2019011343A MX2019011343A MX2019011343A MX2019011343A MX 2019011343 A MX2019011343 A MX 2019011343A MX 2019011343 A MX2019011343 A MX 2019011343A MX 2019011343 A MX2019011343 A MX 2019011343A MX 2019011343 A MX2019011343 A MX 2019011343A
Authority
MX
Mexico
Prior art keywords
purification
antibody fragments
recombinant antibody
relates
present
Prior art date
Application number
MX2019011343A
Other languages
English (en)
Inventor
Sharad Bhambure Rahul
Mahammadtaki Gani Kayanat
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of MX2019011343A publication Critical patent/MX2019011343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un procedimiento de purificación de fragmentos de anticuerpos recombinantes de cuerpos de inclusión expresados en células microbianas; más particularmente, la presente invención se refiere a un procedimiento para la purificación de fragmentos de anticuerpos humanizados recombinantes (rHu), Ranibizumab de cuerpos de inclusión expresados en células microbianas.
MX2019011343A 2017-03-24 2018-03-23 Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes. MX2019011343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711010410 2017-03-24
PCT/IN2018/050164 WO2018173075A1 (en) 2017-03-24 2018-03-23 A process for the purification of recombinant antibody fragments

Publications (1)

Publication Number Publication Date
MX2019011343A true MX2019011343A (es) 2019-11-18

Family

ID=62044783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011343A MX2019011343A (es) 2017-03-24 2018-03-23 Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.

Country Status (9)

Country Link
US (1) US11697672B2 (es)
EP (1) EP3601332A1 (es)
JP (1) JP7655610B2 (es)
KR (2) KR20190131082A (es)
CN (1) CN110582510B (es)
BR (1) BR112019019613A2 (es)
CA (1) CA3057286A1 (es)
MX (1) MX2019011343A (es)
WO (1) WO2018173075A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947694A4 (en) * 2019-04-02 2023-01-04 Council of Scientific & Industrial Research CLONING AND EXPRESSION OF AN IN VIVO REFOLDED ANTIBODY FRAGMENT

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236634T3 (es) * 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
CA2838814A1 (en) * 2011-08-25 2013-02-28 F.Hoffmann-La Roche Ag Cation and anion exchange chromatography method
WO2013158279A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
LT2895188T (lt) * 2012-09-11 2018-04-10 Coherus Biosciences, Inc. Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas
RU2646098C2 (ru) * 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
HUE038741T2 (hu) * 2013-05-06 2018-11-28 Sanofi Sa Folyamatos többlépéses eljárás antitestek tisztítására
WO2015061526A1 (en) * 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
PT3116891T (pt) * 2014-03-10 2020-05-18 Richter Gedeon Nyrt Purificação de imunoglobulina utilizando passos de pré-limpeza
LT3337820T (lt) * 2015-08-17 2021-02-10 Lupin Limited Patobulintas antikūnų fragmentų refoldingo būdas

Also Published As

Publication number Publication date
CN110582510B (zh) 2023-09-15
CN110582510A (zh) 2019-12-17
KR20190131082A (ko) 2019-11-25
US11697672B2 (en) 2023-07-11
KR20240049657A (ko) 2024-04-16
JP7655610B2 (ja) 2025-04-02
BR112019019613A2 (pt) 2020-04-14
KR102774707B1 (ko) 2025-02-27
JP2020511516A (ja) 2020-04-16
US20200095277A1 (en) 2020-03-26
WO2018173075A1 (en) 2018-09-27
EP3601332A1 (en) 2020-02-05
CA3057286A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
IN2013MU02145A (es)
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12022551228A1 (en) Trem2 antibodies and uses thereof
MY176522A (en) Production of t cell retargeting hetero-dimeric immunoglobulins
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX390701B (es) Manufactura de proteína.
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
GB201911685D0 (en) Process for purifying monoclonal antibodies
CA2983057C (en) CLEARANCE METHOD FOR ANTIBODIES CONTAINING VH3
SG10201807572PA (en) Robust antibody purification
EP4273165A3 (en) Interferon beta antibodies and uses thereof
CO2018010286A2 (es) Método para la purificación de proteínas
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
MX2019013750A (es) Un metodo para producir ranibizumab humanizado recombinante replegado.
GB201919058D0 (en) Multi-specific antibodies
GB201919061D0 (en) Multi-specific antibody
AU2018253555A1 (en) Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
IL284402A (en) A process for the production, isolation and purification of modified recombinant proteins
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20